Development of acute myeloid leukemia in patients with untreated chronic lymphocytic leukemia

Ann Hematol. 2017 May;96(5):719-724. doi: 10.1007/s00277-017-2933-x. Epub 2017 Feb 1.

Abstract

The development of acute myeloid leukemia (AML) in patients with untreated chronic lymphocytic leukemia (CLL) is rare. We experienced a 65-year-old man who developed AML with aberrant CD7 expression and monoallelic CEBPA mutation during watchful waiting for CLL. He failed to achieve complete response (CR) by standard induction therapy for AML. We retrospectively reviewed 27 patients who developed AML with untreated CLL published between 1973 and 2016. The median age at diagnosis of AML was 68 years, and the median duration between the diagnoses of AML and CLL was 4.2 years. Diagnosis of AML and CLL was made simultaneously in 16 patients. The CR rate of AML was 42.9%, and the median survival was only 1.5 months after the diagnosis of AML. Patients who achieved CR tended to survive longer than those who did not. Our results demonstrated that the development of AML in patients with untreated CLL was associated with a poor response to chemotherapy and an extremely poor prognosis.

Keywords: Acute myeloid leukemia; Chemotherapy; Chronic lymphocytic leukemia; Secondary leukemia.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Biomarkers
  • Bone Marrow / pathology
  • Fatal Outcome
  • Humans
  • Immunophenotyping
  • In Situ Hybridization, Fluorescence
  • Incidence
  • Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology*
  • Leukemia, Myeloid, Acute / diagnosis*
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / etiology*
  • Leukemia, Myeloid, Acute / mortality
  • Male
  • Neoplasm Staging
  • Neoplasms, Second Primary / diagnosis*
  • Neoplasms, Second Primary / drug therapy
  • Neoplasms, Second Primary / etiology*
  • Neoplasms, Second Primary / mortality
  • Remission Induction
  • Survival Analysis
  • Treatment Outcome

Substances

  • Biomarkers